News Column

Avidity NanoMedicines Scientific Co-Founder to Get Prince of Asturias Award

June 14, 2014

Avidity NanoMedicines said that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

According to a release from the company, Davis is the Warren and Katharine Schlinger Professor of Chemical Engineering at Caltech and was recognized, along with Avelino Corma Canos of the Institute of Chemical Technology in Spain and Galen D. Stucky of UC Santa Barbara, for contributions to the development of microporous and mesoporous materials and various applications of these materials from the petrochemical industry to health care.

In recognition of this year's awardees, the Prince of Asturias Foundation said in part, "The scientific and technical contributions of these three chemists have opened up very important lines of research that are on the frontiers of current knowledge, with direct applications in the reduction of pollutant emissions from vehicles and factories as well as in the processes of refining petroleum and in the chemical industry in general."

"Mark Davis is an exceptional scientist and has made many pioneering contributions to the discovery and development of new materials for applications in catalysis, energy and medicine," said Troy Wilson, J.D., Ph.D., President and Chief Executive Officer of Avidity NanoMedicines. "On behalf of everyone at Avidity, we are honored to be working with him on the development of targeted, polymeric nanoparticles as a new class of medicines, and we congratulate him on this well-deserved honor."

Avidity NanoMedicines said that Davis, recognized as a pioneer in the field of nanotechnology, has been elected to the National Academy of Engineering, the Institute of Medicine, and the National Academy of Sciences.

In addition to co-founding Avidity NanoMedicines, Davis previously founded Insert Therapeutics as well as Calando Pharmaceuticals, a company that demonstrated the first example of RNA interference in a human patient.

Davis will receive the Prince Asturias Award from His Royal Highness The Prince of Asturias at an academic ceremony in October in Oviedo, Spain.

Avidity NanoMedicines is a biopharmaceutical company developing therapeutics, antibody siRNA complexes (ARCs), which draw on the best features of antibody-drug conjugates and nucleic acid-based medicines.

((Comments on this story may be sent to newsdesk@closeupmedia.com))


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Professional Services Close - Up


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters